The ASCENDE-RT trial showed that oncological outcomes were improved among both intermediate-risk and high-risk men who were treated with external beam radiation (EBRT) and a brachytherapy boost (LDR-BT) to the prostate and adjuvant androgen deprivation therapy (ADT) (see this link). A new study from the University of Michigan suggests that the benefit in intermediate-risk men is exclusively among those […]![]()
